Phase 4 N=56 Cognitive Outcomes in Stable Renal Transplant Patients Switched fromTacrolimus to Envarsus XR™
Renal Transplant
Primary: Change in Cognitive Function-Global on Covid-19 Telephone Battery — 34; 9; 10; 10 Units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=165 Brain Health Together: A Live-Streaming Group-Based Digital Program
Mild Cognitive Impairment · Cognitive Decline · Cognitive Deterioration
Primary: Creyos Cognitive Composite - 3 Month — 0.27; 0.13 Change on z-score — p=0.346
Phase 1 N=120 A Study to Evaluate the Safety, Tolerability, and Immunogenicity of the rSm-p80 + GLA-SE (SchistoShield®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar
Schistosomiasis
Primary: Proportion of Participants With of Any Serious Adverse Events (SAEs)/ Adverse Events of Special Interest (AESI) From the Time of the First Study Vaccination Through the…
N/A N=21 Measuring Intraabdominal Pressure, Lactic Acid, and Urine Output
Intra-Abdominal Hypertension · Inguinal Hernia
Primary: Intraabdominal Pressure — 25.58 mmHg
N/A N=40 Broccoli Extract Supplementation in Older Adults With Alcohol Use Disorder
Alcohol Use Disorder
Primary: Gut Leak — 2.60; 3.23; 26.75; 28.57 ng/mL
N/A N=17 Slow Yogic-Derived Breathing and Respiration and Cardiovascular Variability in Spinal Cord Injury Patients
Spinal Cord Injuries · Slow Breathing
Primary: HRV — 1421; 813; 3173; 2819 ms^2
Phase 1 N=42 Study on Sapropterin Dihydrochloride Oral Suspension in Healthy Subjects Under Fed Conditions
Bioequivalence
Primary: Uncorrected and Baseline-corrected Sapropterin AUCt — 819.78; 805.79; 757.73; 755.15 hr*ng/mL
Phase 3 N=256 Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas
Neuroendocrine Tumors · Advanced Cancer
Primary: Efficacy of Axitinib in Terms of PFS (Investigator Assessment) — 17.2; 13.1 months — p=0.324
Phase 3 N=1,049 A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals
SARS-CoV-2 Infection · COVID-19
Primary: Percentage of Participants With Local Reactions Within 7 Days After Vaccination: SSA — 10.0; 4.0; 5.8; 5.4 Percentage of participants
N/A N=23 Sistas Informing Sistas on Topics About AIDS and Prevention (SISTA-P)
Health Behavior, Risky · Health Knowledge, Attitudes, Practice · Health-Related Behavior
Primary: Feasibility of the Intervention Scale — 4.78 units on a scale — p=.001
N/A N=200 Urine Tenofovir Point-of-care Test to Identify Patients in Need of ART Adherence Support (UTRA Study)
Risk Reduction
Primary: Proportion of Participants in Each Arm Achieving Viral Suppression to <50 Copies/ml — 59; 48 Participants
N/A N=10 Adapting and Piloting Behavioral Activation for Veterans With Alcohol Use Disorder and Posttraumatic Stress Disorder
Alcohol Use Disorder · Posttraumatic Stress Disorder
Primary: Timeline Follow-Back (Alcohol Use) — 4.36; 3.90; 1.82; 3.31 Drinks per day — p=0.4174
N/A N=30 CLinical Evaluation of Aspiration for Removal ANd ClearancE of Stones
Renal Stones · Kidney Stone · Urolithiasis
Primary: Stone Clearance (% Reduction in Stone Volume) — 96.2 % stone volume removed
N/A N=8 Pilot Study PBSCT With TCRab Depletion For Hemoglobinopathies
Sickle Cell Disease · Thalassemia Major
Primary: Rate of Graft Failure — 2; 0 participants
N/A N=125 Self-Management and Resilience Trajectories in African American Adults With Hypertension
Hypertension · Self-Management · Quality of Life
Primary: Systolic Blood Pressure — 138.35; 135.56 mmHg — p=0.0050